Pharma Ming Biotechnology Co., Ltd. (the “Company”) will hold its Annual General Meeting on 19 June 2024 at the Sheraton Shanghai Takahashi Hotel in the Shanghai Free Trade Pilot Zone, Shanghai, China. The meeting will address a range of issues including the acceptance of the 2023 audited consolidated financial statements, the Board's reports and the independent auditor's report. In addition, the Board of Directors will be re-elected, including Dr. Chow Wai Chang, Dr. Wu Yibing, Mr. William Robert Keller and Dr. Chan Hui. THE MEETING WILL ALSO AUTHORIZE THE BOARD TO DETERMINE THE REMUNERATION OF DIRECTORS AND TO RENEW DILIGENT ACCOUNTANTS AS ACTING AUDITORS. THE GENERAL MEETING WILL ALSO CONSIDER THE ADOPTION OF ORDINARY RESOLUTIONS AUTHORIZING DIRECTORS TO ISSUE AND...Show More

Pharma Ming Biotechnology Co., Ltd. (the “Company”) will hold its Annual General Meeting on 19 June 2024 at the Sheraton Shanghai Takahashi Hotel in the Shanghai Free Trade Pilot Zone, Shanghai, China. The meeting will address a range of issues including the acceptance of the 2023 audited consolidated financial statements, the Board's reports and the independent auditor's report. In addition, the Board of Directors will be re-elected, including Dr. Chow Wai Chang, Dr. Wu Yibing, Mr. William Robert Keller and Dr. Chan Hui. THE MEETING WILL ALSO AUTHORIZE THE BOARD TO DETERMINE THE REMUNERATION OF DIRECTORS AND TO RENEW DILIGENT ACCOUNTANTS AS ACTING AUDITORS. THE GENERAL MEETING WILL ALSO CONSIDER THE ADOPTION OF ORDINARY RESOLUTIONS AUTHORIZING DIRECTORS TO ISSUE AND PROCESS SHARES WITHIN A SPECIFIED PERIOD, AS WELL AS ORDINARY RESOLUTIONS TO REPURCHASE SHARES OF THE COMPANY. Finally, a motion to approve the adoption of the fourth revised and revised Articles of Association of the Company is hereby approved. The Notice of the General Meeting and related documents was published on 24 May 2024 and can be viewed on the Company's website and on the website of Hong Kong Trading and Settlement Limited.